RT @AlzamendNeuro: ALZN002 is an immunotherapeutic dendritic cell-based vaccine anticipated to begin Phase I/IIA trial in Q1. The inventor…
RT @AlzamendNeuro: ALZN002 is an immunotherapeutic dendritic cell-based vaccine anticipated to begin Phase I/IIA trial in Q1. The inventor…
ALZN002 is an immunotherapeutic dendritic cell-based vaccine anticipated to begin Phase I/IIA trial in Q1. The inventor of ALZN002 is one of the authors of this publication.. #Alzheimers $ENDALZ $ALZN https://t.co/zS4Frjo8i6
RT @AlzamendNeuro: ALZN002 is a journey that started nearly 20 years ago. We recently received a “Study May Proceed” Letter from the FDA to…
RT @AlzamendNeuro: ALZN002 is a journey that started nearly 20 years ago. We recently received a “Study May Proceed” Letter from the FDA to…
ALZN002 is a journey that started nearly 20 years ago. We recently received a “Study May Proceed” Letter from the FDA to begin our Phase 1/IIA clinical trial. The inventor of ALZN002 is one of the authors of this publication.. #Alzheimers #ENDALZ $ALZN ht
RT @AlzamendNeuro: AL002 is an adjuvant-free therapeutic vaccine designed for the treatment and prevention of Alzheimer’s Disease. The inve…
AL002 is an adjuvant-free therapeutic vaccine designed for the treatment and prevention of Alzheimer’s Disease. The inventor of AL002 is one of the authors of this publication... We aim to submit IND for AL002 this month. @alzassociation #Alzheimers $ALZN
"An adjuvant-free vaccine with different Aβ peptides can be an effective & safe approach against Alzheimer's." https://t.co/DRmMGyFi09